Molecular pathogenesis of ovarian borderline tumors

New insights and old challenges

Research output: Contribution to journalArticle

Abstract

Ovarian borderline (low malignant potential) tumors are a puzzling group of neoplasms that do not fall neatly into benign or malignant categories. Their behavior is enigmatic, their pathogenesis unclear, and their clinical management controversial, especially for serous borderline tumors (SBT), the most common type of ovarian borderline tumor. Clarifying the nature of borderline tumors and their relationship to invasive carcinoma has puzzled investigators since the category was created over 30 years ago. Much of the confusion and controversy concerning these tumors is due to a lack of understanding of their pathogenesis and an absence of a model for the development of ovarian carcinoma. This review summarizes recent molecular studies of ovarian borderline tumors with special emphasis on the role of SBT in tumor progression and its relationship to ovarian serous carcinoma.

Original languageEnglish (US)
Pages (from-to)7273-7279
Number of pages7
JournalClinical Cancer Research
Volume11
Issue number20
DOIs
StatePublished - Oct 15 2005

Fingerprint

Neoplasms
Carcinoma
Research Personnel

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Molecular pathogenesis of ovarian borderline tumors : New insights and old challenges. / Shih, Ie Ming; Kurman, Robert J.

In: Clinical Cancer Research, Vol. 11, No. 20, 15.10.2005, p. 7273-7279.

Research output: Contribution to journalArticle

@article{77884721431a4723b7015bc07da83b8b,
title = "Molecular pathogenesis of ovarian borderline tumors: New insights and old challenges",
abstract = "Ovarian borderline (low malignant potential) tumors are a puzzling group of neoplasms that do not fall neatly into benign or malignant categories. Their behavior is enigmatic, their pathogenesis unclear, and their clinical management controversial, especially for serous borderline tumors (SBT), the most common type of ovarian borderline tumor. Clarifying the nature of borderline tumors and their relationship to invasive carcinoma has puzzled investigators since the category was created over 30 years ago. Much of the confusion and controversy concerning these tumors is due to a lack of understanding of their pathogenesis and an absence of a model for the development of ovarian carcinoma. This review summarizes recent molecular studies of ovarian borderline tumors with special emphasis on the role of SBT in tumor progression and its relationship to ovarian serous carcinoma.",
author = "Shih, {Ie Ming} and Kurman, {Robert J}",
year = "2005",
month = "10",
day = "15",
doi = "10.1158/1078-0432.CCR-05-0755",
language = "English (US)",
volume = "11",
pages = "7273--7279",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "20",

}

TY - JOUR

T1 - Molecular pathogenesis of ovarian borderline tumors

T2 - New insights and old challenges

AU - Shih, Ie Ming

AU - Kurman, Robert J

PY - 2005/10/15

Y1 - 2005/10/15

N2 - Ovarian borderline (low malignant potential) tumors are a puzzling group of neoplasms that do not fall neatly into benign or malignant categories. Their behavior is enigmatic, their pathogenesis unclear, and their clinical management controversial, especially for serous borderline tumors (SBT), the most common type of ovarian borderline tumor. Clarifying the nature of borderline tumors and their relationship to invasive carcinoma has puzzled investigators since the category was created over 30 years ago. Much of the confusion and controversy concerning these tumors is due to a lack of understanding of their pathogenesis and an absence of a model for the development of ovarian carcinoma. This review summarizes recent molecular studies of ovarian borderline tumors with special emphasis on the role of SBT in tumor progression and its relationship to ovarian serous carcinoma.

AB - Ovarian borderline (low malignant potential) tumors are a puzzling group of neoplasms that do not fall neatly into benign or malignant categories. Their behavior is enigmatic, their pathogenesis unclear, and their clinical management controversial, especially for serous borderline tumors (SBT), the most common type of ovarian borderline tumor. Clarifying the nature of borderline tumors and their relationship to invasive carcinoma has puzzled investigators since the category was created over 30 years ago. Much of the confusion and controversy concerning these tumors is due to a lack of understanding of their pathogenesis and an absence of a model for the development of ovarian carcinoma. This review summarizes recent molecular studies of ovarian borderline tumors with special emphasis on the role of SBT in tumor progression and its relationship to ovarian serous carcinoma.

UR - http://www.scopus.com/inward/record.url?scp=27144519156&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27144519156&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-05-0755

DO - 10.1158/1078-0432.CCR-05-0755

M3 - Article

VL - 11

SP - 7273

EP - 7279

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 20

ER -